Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:prodrug |
| gptkbp:approvedBy |
gptkb:FDA
2011 (US) |
| gptkbp:ATCCode |
N03AX24
|
| gptkbp:brand |
gptkb:Horizant
Regnite |
| gptkbp:CASNumber |
1041370-39-7
|
| gptkbp:chemicalFormula |
C16H27NO6
|
| gptkbp:developedBy |
gptkb:XenoPort
|
| gptkbp:eliminationHalfLife |
5-7 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Arbor_Pharmaceuticals
GlaxoSmithKline |
| gptkbp:metabolism |
hydrolysis
|
| gptkbp:prodrugOf |
gptkb:gabapentin
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
fatigue headache drowsiness |
| gptkbp:UNII |
6B9H1V8A4V
|
| gptkbp:usedFor |
gptkb:restless_legs_syndrome
postherpetic neuralgia |
| gptkbp:bfsParent |
gptkb:XenoPort
gptkb:Horizant |
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
gabapentin enacarbil
|